Zongertinib 60 mg tablets contain the active ingredient Zongertinib, an investigational targeted anti-cancer medicine belonging to the class of tyrosine kinase inhibitors (TKIs). It is designed to selectively inhibit mutations of the HER2 (Human Epidermal Growth Factor Receptor 2) gene that are involved in the growth and survival of certain cancer cells.

Zongertinib is being studied and developed for the treatment of advanced or metastatic cancers driven by HER2 mutations, particularly non-small cell lung cancer (NSCLC). The medicine works by blocking the abnormal HER2 signaling pathway that promotes cancer cell growth and proliferation.

Patients should not take this medicine if they are allergic to Zongertinib or any components of the formulation. Before starting treatment, inform your doctor if you have a history of liver disease, heart problems, or lung disorders.

Zongertinib is being developed for the treatment of:

HER2-mutant non-small cell lung cancer (NSCLC).

HER2-positive solid tumors.

Advanced or metastatic cancers with confirmed HER2 genetic mutations.

Patients must undergo molecular diagnostic testing to confirm HER2 mutation status before starting therapy.

Zongertinib is a highly selective HER2 tyrosine kinase inhibitor that works by blocking abnormal signaling pathways that promote tumor growth.

By inhibiting HER2 activity, Zongertinib may:

Prevent cancer cell proliferation.

Slow down cancer cell growth.

Reduce tumor progression.

Improve disease control in HER2-mutated cancers.

Targeted therapies like Zongertinib focus on specific molecular alterations in cancer cells, helping reduce damage to normal cells.

Take Zongertinib tablets exactly as prescribed by your healthcare provider.

Swallow the tablets whole with water.

Do not crush, chew, or break the tablets.

Tablets may generally be taken with or without food.

The dose and duration of treatment will depend on the patient’s medical condition and physician recommendations.

Common side effects may include:

Diarrhea

Nausea

Fatigue

Rash

Decreased appetite

Serious side effects may include:

Lung inflammation

Elevated liver enzymes

Severe gastrointestinal reactions

Patients should seek medical attention if severe symptoms occur.

Patients should inform their healthcare provider about all medicines they are taking, including:

Prescription medications

Over-the-counter medicines

Vitamin supplements

Herbal products

Some medications may affect how Zongertinib works, including:

Strong CYP3A inhibitors or inducers

Certain antifungal medicines

Some antibiotics

Other anti-cancer drugs

Your doctor may adjust the dosage if drug interactions occur.

Store at 15°C – 30°C (room temperature).

Keep tablets in the original packaging.

Protect from moisture and heat.

Keep out of reach of children.

Patients should undergo genetic testing to confirm HER2 mutation before starting therapy.

Regular medical monitoring is recommended during treatment.

Follow the prescribed dosage schedule carefully and do not stop treatment without consulting your physician.

Important Note:

Zongertinib is a targeted therapy currently under clinical development and regulatory evaluation in several regions, and availability may vary depending on country-specific approvals.